

Press Release

Business development in new market USA exceeds expectations

- Purchase orders for 9 Exentis3D production systems received
- ♦ Order volume approx. CHF 20 million
- 10 production systems sold to the US in total already this year

Stetten, Switzerland, December 11, 2024 – Exentis Group AG, provider of the only 3D technology platform worldwide that enables industrial large-scale manufacturing, has received several purchase orders in the fourth quarter for the delivery of a total of 9 Exentis 3D production systems to the USA. The order volume amounts to approx. CHF 20 million.

Gürsel Demircali, Chief Commercial Officer of Exentis Group AG: "The recent purchase orders for Exentis production systems are a great success in our efforts to further grow our footprint in the USA, the world's most important market for industrial additive manufacturing solutions. They are a clear indication that the Exentis technology platform for manufacturing millions of ultra-fine industrial parts or tablets with a freely adjustable drug delivery profile in the human body is becoming increasingly established on the market – with the advantage of completely free choice of materials or active pharmaceutical ingredients within a highly sustainable manufacturing process."

With the recent orders, Exentis has already sold a total of 10 production systems to the USA in 2024 and is consistently continuing its international expansion. Demand from other US customers in a wide range of industries remains strong and exceeds initial expectations for the US market, where Exentis has only been active for about a year. The large number of ongoing customer projects will result in multiple further development projects, contract manufacturing orders as well as additional orders for Exentis 3D production systems and license agreements in the future.

About Exentis

As a solution provider, Exentis has the only proprietary 3D technology platform worldwide that allows for industrial large-scale production. Industrialized Additive Manufacturing is universally applicable. For industrial or clean room applications. With free choice of materials, such as metals, ceramics, polymers, pharmaceutical or bioprinting products. The highly flexible 3D production technology combines rework-free component geometries with advantageous cost-benefit ratios. The cold printing process in use is sustainable and conserves materials as well as resources. Our customers, the Exentis 3D community members, can choose between exclusive in-house manufacturing under license agreements or having Exentis produce millions of applications for them as a contract manufacturer.

For further information please contact:

Benjamin del Fabro Head of Investor Relations

+41 44 520 46 00 b.delfabro@exentis-group.com

Visit us also on our website at www.exentis-group.com.